Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GEMELLI 1
- Sponsors Sanofi
- 15 Feb 2019 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated